Why the study?
Do new oral anticoagulants prevent venous thromboembolic events in patients undergoing elective total hip and knee arthroplasty compared to current agents?
Do new oral anticoagulants prevent venous thromboembolic events in patients undergoing elective total hip and knee arthroplasty compared to current agents?
The review highlights the clinical need for new oral, fixed-dose anticoagulants for thromboprophylaxis following elective hip and knee arthroplasty to overcome the limitations of traditional therapies.
Answers are grounded in this paper and cite their sources.
Unmet need for convenient post-arthroplasty thromboprophylaxis persists; leaves open development and testing of new fixed-dose oral agents.
Anticoagulant drugs reduce the risk of venous thromboembolic events after total hip and knee arthroplasty. However, the use of current drugs, such as low molecular weight heparins, is hampered by their subcutaneous route of administration. The use of vitamin K antagonists is hampered by the requirement for routine coagulation monitoring and dose titration to provide effective anticoagulation without an increased risk of bleeding and numerous food and drug interactions. Clearly, there is a need for new oral, fixed-dose anticoagulant drugs that do not require coagulation monitoring, while demonstrating similar or better efficacy and safety profiles when compared with current agents.
No takes yet. Share an insight, caveat, or question.
Richard J. Friedman (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: